MC-1 Fails to Improve Outcomes of Coronary Artery Bypass Grafting

Another promising agent to protect against ischemia-reperfusion injury disappoints in a phase III trial.

Although coronary artery bypass grafting for multivessel coronary artery disease has dramatically improved patient survival and quality of life, complications related to ischemia-perfusion injury are common. MC-1, a pyridoxine metabolite that prevents calcium overload, has been touted as a novel therapy to reduce ischemia-reperfusion injury, and phase II clinical data has suggested that it might decrease the rate of adverse events in high-risk CABG patients. In the manufacturer-funded MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery II (MEND-CABG II) trial, investigators randomized >3000 intermediate- to high-risk patients undergoing CABG in Canada, the U.S., and Germany to either MC-1 (250 mg/day) or placebo. T…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)